Saturday, August 9, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

A third Covid vaccine dose improves defence for some clinically extremely vulnerable patients

May 8, 2024
in Cancer
Reading Time: 3 mins read
0
66
SHARES
602
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT
ADVERTISEMENT

A major clinical trial has found that an additional COVID 19 vaccine dose led to the majority of clinically extremely vulnerable people mounting defensive antibodies against Covid-19.

A major clinical trial has found that an additional COVID 19 vaccine dose led to the majority of clinically extremely vulnerable people mounting defensive antibodies against Covid-19.

 

New research published in The Lancet Rheumatology from the OCTAVE DUO research trial co-led by the University of Birmingham and University of Glasgow found that vaccine boosters led to improved antibody responses among many groups of immunocompromised and immunosuppressed patients.

 

Co-funded by the Government and Blood Cancer UK and supported by the National Institute for Health and Care Research (NIHR), this trial opened in 11 hospitals across the UK and recruited 804 patients across nine disease areas, all of whom had previously mounted low or no immune response from an initial two doses of the vaccines.

 

Among those who mounted a low immune response, 90% patients who received a third vaccine dose went onto develop significant antibody levels.

 

However, more than half (54%) of ‘non-respondents’ from the initial vaccine course still saw no relevant antibody increase. Furthermore, the study found that those with lymphoid disease and chronic renal disease had the worst antibody mounting outcomes from boosters.

 

The OCTAVE DUO study also found:

  • some drugs reduced antibody response including treatments for autoimmune diseases and cancers – specifically B Cell targeted therapy and antimetabolites.
  • T Cell response was mounted for 80% of all participants, including more than half (55%) of those previously not showing any T Cells after two vaccinations.

 

Pamela Kearns, Professor of Clinical Paediatric Oncology and Director of the Institute of Cancer and Genomic Sciences at the University of Birmingham, and a lead investigator of the trial said:

 

“The Covid booster programme has been shown to have an important protective effect for many of the most clinically vulnerable members of society for whom the initial two doses were insufficient. In the OCTAVE DUO study, we tracked those who mounted little or no antibody defences following two initial doses of a vaccine. It is encouraging to see that boosters helped to increase antibody defences 9 in 10 participants who hadn’t previously mounted a defence after two jabs.

 

“However, more than half of those who didn’t respond at all to an initial course of vaccines didn’t develop any antibody defence after boosters. This underscores the need for other protective factors to support the most clinically vulnerable in society and continue to be vigilant against Covid in society.”

 

Professor Iain McInnes, Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow and Chief Investigator for the OCTAVE Consortium, said:

 

“Our first OCTAVE study revealed a group of patients who may not mount a sufficient immune response following a vaccine dose, which is why the OCTAVE DUO study is so important. For the clinically vulnerable in our society, the vaccine booster programme offers important protection, therefore further understanding of the effectiveness of vaccines in people with immune-mediated inflammatory diseases is extremely important. It is encouraging to see the results of OCTAVE DUO, which provides important answers and reinforces the need to support and protect patients who are more clinically vulnerable.”



Journal

The Lancet Rheumatology

DOI

10.1016/S2665-9913(24)00065-1

Method of Research

Randomized controlled/clinical trial

Subject of Research

People

Article Title

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an openlabel, multicentre, randomised, controlled, phase 3 trial

Article Publication Date

8-May-2024

Share26Tweet17
Previous Post

Study: Neuropathy very common, underdiagnosed

Next Post

Inconclusive evidence suggests zinc may slightly shorten common cold

Related Posts

Cancer

Revolutionizing Fetal Congenital Heart Disease: MRI’s Impact

August 9, 2025
blank
Cancer

Enhancing Pediatric Abdominal MRI Quality with Deep Learning

August 9, 2025
blank
Cancer

FAM111B Knockdown Suppresses Ovarian Cancer by Downregulating MYC

August 9, 2025
blank
Cancer

Lung Ultrasound Transforms Neonatal and Pediatric Respiratory Care

August 9, 2025
blank
Cancer

Understanding Tenosynovial Giant Cell Tumors in Kids

August 9, 2025
blank
Cancer

120 mmHg Limit: Key to Safe Intussusception Reduction

August 8, 2025
Next Post
Inconclusive evidence suggests zinc may slightly shorten common cold

Inconclusive evidence suggests zinc may slightly shorten common cold

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27531 shares
    Share 11009 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    943 shares
    Share 377 Tweet 236
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    507 shares
    Share 203 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Revolutionizing Fetal Congenital Heart Disease: MRI’s Impact
  • Distinct Coral Reef Regions Identified in Red Sea
  • Scientists Discover Novel Mechanism Behind Cellular Tolerance to Anticancer Drugs
  • Enhancing Pediatric Abdominal MRI Quality with Deep Learning

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,860 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading